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Resveratrol (3, 40 , 5-trihydroxy-trans-stilbene) is a natural phytoalexin found in grapes
and has long been thought to be the answer to the “French Paradox.” There is no
shortage of preclinical and clinical studies investigating the broad therapeutic activity
of resveratrol. However, in spite of many comprehensive reviews published on the
bioactivity of resveratrol, there has yet to be a report focused on the variety and
complexity of its structural binding properties, and its multi-targeted role. An improved
understanding of disease mechanisms at the systems level has enabled targeted
polypharmacology to mature into a rational drug discovery approach. Unlike traditional
hit-to-lead campaigns that typically optimize activity and selectivity for a single target,
polypharmacological drugs aim to selectively target multiple proteins, while avoiding
critical off target interactions. This strategy bears promise of improved efficacy and
reduced clinical attrition. This review seeks to investigate whether the bioactivity of
resveratrol is due to a polypharmacological effect or promiscuity of the phenolic small
molecule by examining the modes of binding with its diverse collection of protein
targets. We focused on annotated targets, identified via the ChEMBL database, and
matched these targets to a representative structure deposited in the Protein Data Bank
(PDB), as crystal structures are most informative in understanding modes of binding
at the atomic level. We discuss the structural aspects of resveratrol itself that permits
binding to multiple proteins in various signaling pathways. Furthermore, we suggest that
resveratrol’s bioactivity is a result of scaffold promiscuity rather than polypharmacology,
and the variety of binding modes across targets display little similarity in the pattern of
target interaction.
Keywords: resveratrol, polypharmacology, protein targets, receptor, repurposing

INTRODUCTION
Resveratrol (3, 40 , 5-trihydroxy-trans-stilbene) (Figure 1) was first isolated from the roots of
Veratrum grandiflorum in 1940 (Takaoka, 1939), but it is renowned for being present in micromolar
concentrations in red wine grape varietals (Siemann and Creasy, 1992). In fact, resveratrol is often
attributed as the solution to the “French Paradox” which accounts for the lower incidence of
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FIGURE 1 | (A) Three-dimensional chemical structure of resveratrol. Carbon (black), oxygen (red) and hydrogen (cyan). The two chemical moieties are shown as
marked. (Image created by Discovery Studio Visualizer 4.5, Accelrys). (B) Two-dimensional chemical structure of resveratrol.

investigation of protein-ligand interactions, it becomes apparent
that resveratrol’s binding modes vary substantially. We focus our
efforts on published resveratrol co-crystal structure targets to
analyze the molecular interactions underlying resveratrol binding
in an attempt to demonstrate its interfamily target promiscuity
through non-conserved modes of binding.

heart disease even in cases of high saturated fat diets (Renaud and
de Lorgeril, 1992). Resveratrol belongs to a class of antimicrobial
compounds known as phytoalexins, which are often secondary
metabolites synthesized by plants in response to sudden stress
for protection, but not necessary for survival (Ren and Lien,
1997). Resveratrol has demonstrated activity in a myriad of
disease models due to its ability to modulate numerous signaling
pathways. This includes vasodilation (Gordish and Beierwaltes,
2014), platelet aggregation (Wang et al., 2002), cardio-protection
(Wu et al., 2011), chemoprevention (Aziz et al., 2003), anti-viral
(Campagna and Rivas, 2010), neuroprotection against stress and
degeneration (Albani et al., 2010), anti-oxidant (de la Lastra and
Villegas, 2007), and anti-inflammatory properties (Bereswill et al.,
2010). These diverse beneficial effects of resveratrol are mainly
driven by modulation of important proteins such as survivin
(Hayashibara et al., 2002), Bcl2 (Low et al., 2010), p53 (Kai
et al., 2010) sirtuins (SIRT1,3 and 5) (Bagul et al., 2015) and
transcriptional factors like NF-κB (Yin and Cheng, 2005).
While evaluation of the mechanism and therapeutic potential
of resveratrol continues to increase, no concrete structural
basis of resveratrol’s polypharmacology has been proposed
thus far. In the current review, we address the structural
details of resveratrol and its binding with a diverse array of
targets, which are often unrelated by sequence, structure fold,
and even the local binding site and binding interactions. On
the surface, the structural data points to a flexible mode of
binding, suggesting that certain local structural complementarity
triggers resveratrol-target interactions, suggesting there is
some specificity required for binding. However, upon further
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METHODS FOR TARGET SELECTION
Resveratrol bioactivity has been widely explored. To obtain an
overview of resveratrol’s reported known targets, we queried the
ChEMBL 21 database and extracted all existing records as of 2018
(Gaulton et al., 2017). These were filtered by organism: Homo
sapiens; reported assay result/endpoint: IC50, EC50, AC50, Ki,
Kd; potency, unit: nM; and only records with exact endpoint
values (relation: =) and confidence score ≥ 5 were kept. As
we are interested in specific targets of resveratrol, we filtered
and aggregated all the data records in ChEMBL 21 to include
biochemical data for specific single protein targets. All records
were aggregated (as arithmetic average) based on unique protein
target and reported endpoint. The p-values are summarized in
Supplementary Table 1 by protein as indicated by name and
symbol. These targets were then matched with a representative
structure deposited in the PDB. Table 1 describes the targets
discussed in this review, along with function of resveratrol on
these targets, UniProt protein names and gene names. All targets
were prepared using the Schrodinger Maestro suite 2017 Protein
Preparation Wizard to determine optimal protonation states of
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TABLE 1 | Various classes of resveratrol targets and their function discussed in the review.
No

Synonym

Protein name

UniProt ID

PDB ID

Class

Function

1

LTA4H

2

PLA2

Leukotriene A4 hydrolase

P09960

3FTS

Hydrolase

Inhibitor

Phospholipase A2

D0VX11

4QER

Hydrolase

3

Inhibitor

F1-ATPASE

ATP synthase subunit alpha

P19483

2JIZ

Hydrolase

Inhibitor

4

SULT1B1

Sulfotransferase family cytosolic 1B member 1

O43704

3CKL

Transferase

Inhibitor

5

QR2

NRH dehydrogenase [quinone] 2

P16083

1SG0

Oxidoreductase

Inhibitor

6

PPAR-γ

Peroxisome proliferator-activated receptor gamma

P37231

4JAZ

Transcription Regulation

Inhibitor

7

TTR

Transthyretin

P02766

5CR1

Transport protein

Inhibitor

8

cTnC

Troponin C

P63316

2L98

Contractile protein

Inhibitor

9

Myosin-2 motor domain

Myosin-2 heavy chain

P08799

3MNQ

Motor protein

Inhibitor

10

MAT2B

Methionine Adenosyltransferase Subunit beta

Q9NZL9

2YDX

Oxidoreductase

Inhibitor

11

Sirt5

NAD-dependent protein deacetylase sirtuin-5

Q9NXA8

4HDA

Hydrolase

Activator

12

Sirt1

NAD-dependent protein deacetylase sirtuin-1

Q96EB6

5BTR

Hydrolase

Activator

13

ERα

Estrogen receptor

P03372

4PP6

Protein binding

Modulator

14

TyrRS

Tyrosine–tRNA ligase

P54577

4Q93

Ligase

Modulator

residues and ligands, as well as establishing correct bond order to
HET groups, and performing a restrained minimization1 .

in the release of arachidonic acid and lysophospholipids
(Dennis, 1994). These compounds act like hormones in
a number of physiological processes at extremely low
concentrations (Murakami et al., 1999). However, at high
concentrations they serve as precursors for inflammatory
mediators such as eicosanoids or platelet-activating factor
(PAF), hence aiding in inflammation. Resveratrol binds to
PLA2 in the substrate binding cleft hence inhibiting eicosanoid
production, exhibiting an anti-inflammatory activity (Shukla
et al., 2015).
Analysis of the structure of the complex of PLA2 with
resveratrol clearly shows that while most of the compound
is substantially buried in the PLA2 site, parts of the scaffold
remain surface exposed. The less polar 4-hydroxystyryl moiety is
encapsulated in a buried environment in the substrate binding
cleft, while the more electronegative m-hydroquinone ring is
toward the surface of the receptor. Resveratrol formed three
H-bonds, one each with Asp49, His48 and Cys45 via its 4hydroxystyryl moiety, while the m-hydroquinone moiety makes a
very strong H-bond with Leu2 close-by and a weak H-bond with
Gly6 in the vicinity. Two important hydrophobic interactions are
formed with Ile19 and Phe5 located in the vicinity, along with
numerous Van der Waals interactions. All residues involved in
binding to resveratrol belong to either a loop or an alpha helix
(Shukla et al., 2015).

RESVERATROL INHIBITORY BINDING
MODES
Leukotriene A4 Hydrolase (PDB: 3FTS)
Leukotrienes (LTs) are potent proinflammatory lipid
mediators implicated in the pathogenesis and progression
of atherosclerosis (Subbarao et al., 2004). Leukotriene A4
hydrolase (LTA4H) is a 69 kDa zinc-containing bifunctional
enzyme with aminopeptidase and epoxide hydrolase activities.
It converts the oxirane ring of LTA4 to leukotriene B4 (LTB4)
(Samuelsson, 1983). LTB4 is a chemoattractant and an activator
of inflammatory responses mediated by binding to G-proteincoupled receptors. Resveratrol inhibits LTA4H by binding to
LTB4 binding site and thus acts as an anti-inflammatory agent
(Davies et al., 2009).
The structure of resveratrol as an inhibitor with LTA4H
suggests that it buries itself in the 17A◦ long L-shaped leukotriene
A4 substrate binding cleft, where solvent accessibility is very
low. It forms numerous important hydrogen bonds (H-bonds)
with the binding site residues. The m-hydroquinone moiety
of resveratrol binds to the cleft residues like Asp312, Phe362
and Val367. On the other hand, the 4-hydroxystyryl moiety
forms only two important H-bond interactions with Asp375 and
Gln136. Resveratrol also makes hydrophobic interactions with
Gln136, Ala137, and Phe314 via its 4-hydroxystyryl ring and with
Val367, Leu369, and Phe314 with the m-hydroquinone ring. It
was further observed that all these critical residues involved in
resveratrol binding belong to either a loop or a beta sheet.

F1 -ATPase (PDB: 2JIZ)
The ATP synthase is a multi-subunit assembly found prominently
in the inner mitochondrial membrane (Pedersen et al., 2000).
Resveratrol inhibits ATP synthesis by binding to the ATP
synthase (F1Fo-ATPase) found in mitochondria, along with
inhibiting ATP hydrolysis by binding with its separate F1 catalytic
domain (Zheng and Ramirez, 2000). During cardiac ischemia, the
cardio-protective benefits of resveratrol result from inhibition of
hydrolytic activity of F1Fo-ATPase (but not ATP synthesis) in
mitochondria, thus preventing the destruction of ATP that leads
to tissue damage (Zheng and Ramirez, 2000; Hong and Pedersen,
2008).

Phospholipase A2 (PDB: 4QER)
Phospholipase A2 (PLA2) is a superfamily of lipolytic enzymes
that catalyze the hydrolysis of membrane phospholipids resulting
1

https://www.schrodinger.com/
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cofactor FAD. Resveratrol adopts a perfectly flat conformation by
burrowing itself at the QR2 dimeric interface. The two aryl rings
interact with many neighboring residues through hydrophobic
and van der Waals interactions. The m-hydroquinone ring forms
H-bonds with Tyr132 and Asn161, while also participating in
a close pi-pi stacking with Phe178 and similar hydrophobic
interactions with Phe106 and Trp105. The 4-hydroxystyryl
moiety binds with Tyr104 in a pi-pi stacking interaction and
also with Trp105 and Phe126 through hydrophobic interactions.
The 4-hydroxystyryl moiety further interacts through hydrogen
bonding with Thr71 and Asp117. All receptor residues involved
in binding belong to either an alpha helix or a loop.

Resveratrol binds to a highly hydrophobic pocket in F1 ATPase (Gledhill et al., 2007), involving many buried residues
where it acquires a slightly distorted planar conformation
due to many hydrophobic interactions and H-bonds. The
hydrophobic interactions occurring between the resveratrol and
F1 -ATPase involve residues Lys-260, Ile-263, TP-Val279, TPAla278, Glu264 via the m-hydroquinone moiety. While the
hydrophobic interactions with Arg291, Ala256 and Thr259
are via the 4-hydroxystyryl moiety. Val-279 and TP-Glu-292
form H-bonds with the m-hydroquinone and 4-hydroxystyryl
moiety of resveratrol, respectively (Gledhill et al., 2007). Here
again, resveratrol is deeply buried inside the receptor cavity.
Interestingly, all residues involved in binding resveratrol belong
to an alpha helix.

PPAR-γ (PDB: 4JAZ)
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear receptor family of ligand-dependent
transcription factors. Three isoforms of PPAR have been
identified: PPAR-α, PPAR-δ, and PPAR-γ, of which PPAR-γ is
the most extensively studied subtype (Michalik et al., 2006).
PPAR-γ is adipogenic and the inhibitory effect of resveratrol on
adipogenesis is believed to occur through down-regulation of
PPAR-γ mRNA expression in human visceral adipocytes (Fajas
et al., 2001; Floyd et al., 2008). Resveratrol directly binds to and
inhibits the Ligand Binding Domain (LBD) of PPAR-γ, where it
binds to a deep surface cavity in one of the monomer units of the
dimeric structure and not at the interface (Calleri et al., 2014). It
makes several interactions via its m-hydroquinone ring including
an H-bond with Ser342 and two hydrophobic interactions with
Arg288 and Ile341. In order to accommodate the resveratrol
rings, there is partial displacement of a few residues in the
PPAR-γ LBD. The 4-hydroxystyryl ring forms a strong H-bond
with Arg280 and a few hydrophobic interactions including those
with Phe264, His266 and Ile281. All residues involved in binding
resveratrol belong to either an alpha helix or a loop.

Sulfotransfase1B1 (PDB: 3CKL)
The human cytosolic sulfotransferases (hSULTs) comprise a
family of 12 phase II enzymes involved in the metabolism of
drugs and hormones (Blanchard et al., 2004). Sulfotransfase1B1
(SULT1B1) was originally identified as a thyroid hormone SULT.
However, it was later discovered that it conjugates with phenols
(e.g., 4-nitrophenol, 1-naphthol) and is very effective in the
activation and modification of polycyclic hydrocarbons leading
to the activation of carcinogens (Pang, 2011).
The SULT1B1-30 -phosphoadenosine 50 -phosphate(PAP)resveratrol ternary complex structure has an Arg90 which acts
a gating residue guarding the open ligand-bound and closed
unbound conformations of the receptor (Pan et al., 2008,
unpublished data). Resveratrol was found to be sandwiched in
the hydrophobic binding pocket where the m-hydroquinone
ring forms H-bonds with His109 and Thr21, while also forming
pi-staking hydrophobic interactions with Phe24, Phe143, Tyr170,
and Phe143. On the other hand, the 4-hydroxystyryl moiety is
again tied up in hydrophobic interactions with Leu86, Leu149,
Leu244 and Val248 with no neighboring residues to form any
H-bonds. All residues involved in binding resveratrol belong
to either an alpha helix or a loop (Pan et al., 2008, unpublished
data).

Transthyretin (PDB: 5CR1)
Thyroid hormone transport protein transthyretin (TTR) is an
amyloidogenic protein whose mutation or deletion is responsible
for familial amyloidotic polyneuropathy (FAP) (Ando et al.,
2005). The amyloidogenic potential of TTR is enhanced by
a number of specific point mutations. Inhibitory activity of
TTR fibrillogenesis is known for several classes of compounds,
including resveratrol (Santos et al., 2016). Resveratrol binds
to TTR on a shallow surface cavity unlike any of the other
receptors described above (Florio et al., 2015). The few, but
major interactions involved via the m-hydroquinone ring include
a hydrophobic interaction with Leu110 and a hydrogen bond
with Ser117. The 4-hydroxystyryl moiety binds TTR via Lys15
and Ala108 through hydrophobic interactions solely, with no
hydrogen bonding. Interestingly, all interacting residue belong to
the beta sheet of TTR binding site.

Quinone Reductase 2 (PDB: 1SG0)
Quinone reductase 2 (QR2) belongs to the mammalian quinone
reductase family of enzymes responsible for performing flavin
adenine dinucleotide (FAD) mediated reductions of quinone
substrates (Jaiswal, 1994). QR2 is responsible for the generation
of quinone free-radicals that are believed to cause several
neurodegenerative diseases and helicobacter pylori infections
(Wang and Maier, 2004; Wang et al., 2008). Specifically, their
role in the production of oxidative stress has been discussed
at length (Wang and Maier, 2004). Resveratrol binds to QR2,
inhibiting quinone toxicity and has demonstrated impressive
reduction of proliferation rates on a variety of cancer cell
lines (Buryanovskyy et al., 2004). The chemopreventive and
cardioprotective properties attributed to resveratrol are possibly
the result of QR2 inhibition.
In the QR2 active site, resveratrol fits into a deep hydrophobic
cleft (Buryanovskyy et al., 2004). Furthermore, it occupies a
parallel conformation to the isoalloxazine ring of the bound
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Cardiac Regulatory Protein Troponin C
(PDB: 2L98)
Cardiac troponin C (cTnC) is a Ca2+ signaling protein
that triggers heart muscle contraction (Ebashi et al., 1967).
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Intracellular Ca2+ modulation carries risks associated with
calcium overload such as cardiac arrhythmias, cell injury, or
cell death. The role of cTnC as a target protein for the calcium
sensitization is established (Haikala et al., 1995). Resveratrol
increases the myofilament Ca2+ -sensitivity of myocytes in
guinea-pigs by modulating the cTnC -troponin I interaction
through competitive inhibition to cTnC (Liew et al., 2005).
Resveratrol binds to a broad and deep surface cavity of the
cCTnC, where the m-hydroquinone ring is somewhat exposed to
the solvent (Pineda-Sanabria et al., 2011). It undergoes a minor
conformational change upon binding to the hydrophobic pocket
of cCTnC. The resveratrol-cCTnC interaction site is populated
primarily by hydrophobic interactions, such as interactions with
side chains of Leu100, Leu121 via its m-hydroquinone ring. The
4-hydroxystyryl moiety forms a tight pi-pi stacking interaction
with Phe156 and several hydrophobic interactions with Leu136,
Leu117, Met157, Val160 and Phe153. Interestingly, there is no
hydrogen bonding present between resveratrol and the binding
site residues of cCTnC. The binding residues of cCTnC are all
from the nearby alpha helix.

biomolecules (proteins, DNA, RNA, phospholipids) in the cell. Its
enzymatic activity is regulated by the associated subunit MAT2B
(LeGros et al., 2001).
Interestingly, the structure of MAT2B with resveratrol reveals
that there are non-canonical binding sites for resveratrol in
MAT2B structure exhibiting different binding modes in the
protein (Shafqat et al., 2013). One being in the substrate binding
pocket of MAT2B (res1 site) and the other at the dimer interface
(res2 site), which mimics possible contact regions for the MAT2A
and MAT2B interactions.
Res1 binds in a broad but shallow pocket inside the substrate
binding cleft. The binding interactions between res1 and the
substrate include an aromatic pi-pi stacking interaction of the
nicotinamide adenine dinucleotide phosphate (NADP) ring with
the m-hydroquinone ring of res1. Furthermore, the substituted
hydroxyls on the m-hydroquinone ring form H-bonds with
Ser136, Asp137, Tyr159 and Arg219, Ile184. The 4-hydroxystyryl
ring is H-bonded via its hydroxyl group to Glu193 and forms
no hydrophobic interactions. Res2 binds in a deep narrow
pocket within the receptor dimer interface and participates
in a multitude of interactions with the monomeric A and C
chains of this homopentameric complex. These include; two
H-bonds via the m-hydroquinone ring to the acidic C:Glu68 and
C:Asp84 residues and hydrophobic interactions with A:Val332,
C:Ile81, A:Thr331, A:Arg329, C:His80. While the 4-hydroxystyryl
ring makes several hydrophobic interactions like those with
C:His80, A:Asn337, A:His334, C:Ala77 and does not participate
in any hydrogen bonding. The binding residues for both of
the resveratrol conformations belong to all three secondary
structures; alpha helix, beta sheet and loop (Shafqat et al., 2013).

Myosin-2 Motor Domain (PDB: 3MNQ)
Myosin-2 is an ATP-driven molecular motor that plays a
crucial role in cell movement (Wilson et al., 2010). Besides
serving their primary role in muscle contraction, they are
also involved in other cellular processes such as cytokinesis,
cortical tension maintenance, and neurite outgrowth and
retraction. They are implicated in several human diseases such
as hypertrophic cardiomyopathy, cancer, deafness and many
neurological disorders (Aguilar-Cuenca et al., 2014). Movement
by myosin motors is generated by the energy released from the
hydrolysis of ATP by the actin-activated Mg2+ ATPase in the
motor domain. Resveratrol binds to the myosin-ADP-Pi complex
with high affinity and interfering with the phosphate release
process.
Resveratrol binds to a shallow groove on the myosin-2
motor domain surface. The binding of to the receptor includes
mainly H-bond interactions with Thr231, Lys229 and Thr274
via the m-hydroquinone ring. There are hardly any hydrophobic
interactions of the m-hydroquinone ring with non-polar residues
due to sparsity of these residues in the vicinity. However,
the 4-hydroxystyryl ring does make a few weak hydrophobic
interactions with the side chains of Gln662, Leu663, Lys661,
and Asn234. Overall, resveratrol is bound by a small number of
interactions in the myosin-2 motor domain. Uniquely, all these
interacting residues are part of loops surrounding the binding
area and no sole residue belongs to a structured entity like an
alpha helix or a beta sheet.

RESVERATROL ACTIVATING BINDING
MODES
Sirt1 (PDB: 5BTR)
Sirtuins are key regulators of metabolism and activation of
these enzymes by resveratrol has demonstrated therapeutic
potential across several disease models (Bagul et al., 2015).
Human SIRT1 encodes for sirtuin-1 with an extended N-terminal
domain (NTD) and possess intrinsic mechanisms to regulate its
NAD-dependent deacetylase activities (Davenport et al., 2014).
Activation of Sirt1 increases lifespan by mimicking the effect
of caloric restriction in several animal models (Barger et al.,
2008). However, this effect has yet to be translated in primates.
There is significant interest in sirtuin activation by small
molecules for aging and alleviation of metabolic diseases (Howitz
et al., 2003). Cell survival and enhanced metabolic activity
is increased through stimulating Sirt1-dependent deacetylation
of transcription several families of transcription factors, but
notably PPAR-γ Coactivator 1a (PGC-1α) and Forkhead-O-Box
(FOXO) (Howitz et al., 2003; Cantó and Auwerx, 2012), resulting
in increased mitochondrial biogenesis, and autophagy. While
controversial, it appears that resveratrol enhances the preference
of Sirt1 for the bound acetylated substrate and NAD(+).
Resveratrol treatment increases the rate of this deacetylation
event by Sirt1 twofold, as shown in multiple in vitro and in vivo

S-adenosylmethionine Synthetase 2
(PDB: 2YDX)
Methionine adenosyltransferase (MAT) is a key enzyme in
cellular metabolism. It catalyzes the transfer of the adenosyl
moiety from ATP to L-methionine to form S-adenosylmethionine
(SAM) (Mudd and Mann, 1963). SAM plays a critical role in
cellular metabolism as it is the major methyl donor for various
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studies. Resveratrol has thus attracted attention as a prospective
epigenetic therapeutic (Bagul et al., 2015).
The structure of Sirtin complex with resveratrol and a 7amino-4-methylcoumarin (AMC)-containing peptide reveals the
presence of three resveratrol molecules (res1-3), from which two
mediate the interaction between the AMC peptide and the NTD
of Sirt1 (Cao et al., 2015). Res1 and res1 interact with both the
Sirt1 NTD and p53-AMC, while res1 contacts the Sirt1 catalytic
domain (CD) and the peptide. In the res1 conformation, the
m-hydroquinone moiety participates in H-bond interactions with
Glu230 and Lys3 of p53-AMC, and hydrophobic interactions
with Pro447 and Arg446. The 4-hydroxystyryl ring makes
weak hydrophobic interactions with Ile 223 and Leu202 of
the binding site. Res2, located at around 4–5 Å distance from
res1, makes three H-bonds with Phe414, Leu215, Pro212 via its
m-hydroquinone moiety and two with Sirt1 residues Gln222,
Asn226 and one with the AMC-peptide residue, Arg1 via its 4hydroxystyryl ring. While there are no observable hydrophobic
interactions of the m-hydroquinone moiety with the receptor
residues, two close hydrophobic interactions with the receptor
residue Ile223 and the peptide residue Lys3 of the 4-hydroxystyryl
ring. Res3 was located at the opposite side of the coumarin ring
with respect to the locations of res1 and res2. It forms H-bonds
with Asp298, Asp292 and hydrophobic interactions with Gln294,
and Pro212 receptor residues via its m-hydroquinone ring.
The 4-hydroxystyryl ring participates in a paramount H-bond
with Lys444 and a hydrophobic bond with Thr209 of the
receptor molecule. Interestingly, in all the three conformations
the resveratrol molecules occupy a deep narrow surface cleft
on the receptor molecule. The receptor binding residues strictly
belong to either an alpha helix or a loop (Cao et al., 2015).

modulating the activities of transcription factors such as
the activator protein (AP)-1, nuclear factor-κB (NF-κB) and
stimulating protein-1 (Sp-1). ER activation further exerts its
effect by activating many signal transduction pathways including
ERK/MAPK, p38/MAPK, PI3K/AKT, PLC/PKC (Marino et al.,
2006).
Resveratrol is a pathway-selective estrogen receptor-α (ERα)
ligand which aids to modulate the inflammatory response but not
cell proliferation. Resveratrol binding to ERα changes the shape
of the receptor in such a way that it controls which coregulatory
molecules aid in regulation of transcription (Nwachukwu et al.,
2014). ERα adopts a resveratrol-specific conformation due
to a substantial conformational change in the receptor after
resveratrol binding due to the movement and docking of multiple
helices. Resveratrol binds to ERα in two different orientations
(R1 and R2) which make somewhat similar interactions in each
subunit of the dimer.
In R1, the resveratrol m-hydroquinone ring forms two
H-bonds with B:Leu387 and B:Glu353 with no close hydrophobic
interactions, while the 4-hydroxystyryl ring forms an H-bond
with B:His524 and a hydrophobic interaction with B:Leu525.
In R2, the m-hydroquinone ring makes close hydrophobic
interactions with A:Leu525, Met421 and an H-bond with
A:His524. While the 4-hydroxystyryl ring participates in several
hydrophobic interactions with A:Phe404, Ala350, Leu391,
Leu387 and hydrogen bonding with A:Leu387, Glu353 and
Arg394.In both of the conformations, the resveratrol molecule
binds into a deep pocket inside each ER monomer unit. Most
residues participating in resveratrol binding belong to alpha
helices, with only one in a beta sheet (Nwachukwu et al., 2014).

Sirt5 (PDB: 4HDA)

Tyrosyl transfer-RNA (tRNA) synthatase (TyrRS) is a 58 KD
homodimeric enzyme catalyzing the aminoacylation of tRNATyr
by L-tyrosine (Bedouelle, 1990). These class I synthetases play
an important role in protein synthesis and signal transduction
including their primary function to help in translating the genetic
material into the amino-acid building blocks that make proteins
(Kyriacou and Deutscher, 2008). Resveratrol inhibits the catalytic
activity and redirects TyrRS to a nuclear function (Sajish and
Schimmel, 2015). It does this by mimicking the natural substrate
tyrosine and fits tightly into TyrRS’s tyrosine binding pocket.
This binding event takes TyrRS away from its protein translation
role and steers it to a function in the cell nucleus (Sajish and
Schimmel, 2015).
The binding interactions between resveratrol and TyrRS
predominantly involves pi-pi stacking interactions of Tyr166 and
His77 via the m-hydroquinone ring of resveratrol. Furthermore,
resveratrol also makes hydrophobic contacts with the side-chains
of Ile191 and Val152 and H-bonds with Tyr166, Gln170. The
4-hydroxystyryl ring forms a pi-pi stacking interaction with
His77, hydrophobic interactions with Tyr39, Leu72, Ala74 and
H-bonds with Tyr39 and Asp173 residues of the TyrRS active
site. Once again, the resveratrol is sitting in a deep surface
cavity of the TyrRS structure. Most of the binding residues
are from an alpha helix with very few in a close-by beta
sheet.

Tyrosyl tRNA Synthatase (4Q93)

Sirtuin-5 (Sirt5) is predominantly expressed in lymphoblasts
and heart muscle and is a multifunctional protein that plays
a key role in cellular metabolism, along with Sirt1 (Haigis
et al., 2006). Resveratrol activates Sirt5 by closing the active site
opening, consequently trapping the bound peptide inside the
cleft which thereby increases the interaction between the peptide
and Sirt5. Resveratrol binding occurs in a deep pocket, such
that it is positioned next to the peptide and directly contacts its
fluorophore plane. The m-hydroquinone ring is making a strong
H-bond with Thr279 and further participates in a hydrophobic
interaction with Thr278 of the receptor binding site. While the
4-hydroxystyryl ring interacts with the FdL1-peptide and makes
close hydrophobic interactions with the side-chains of Arg71,
Gly72 and Gln83. All major binding residues are a part of either
a loop or a helix (Gertz et al., 2012).

RESVERATROL MODULATORY BINDING
MODES
Estrogen Receptor Alpha (PDB:4PP6)
Estrogen Receptor (ER) is activated by binding to 17β-estradiol
(E2). This ligand-activated ER dimerizes and translocate in
the nucleus where it indirectly impacts gene expression by
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MOLECULAR AND FUNCTIONAL
DIVERSITY CHARACTERIZING
RESVERATROL’S
POLYPHARMACOLOGY

classes of proteins are very different, one cannot determine any
functional or evolutionary similarity in the resveratrol targets that
could attribute to its binding to these receptors.

Target Primary Sequence and Structural
Similarity

Analysis of the binding residues of resveratrol in various targets
indicate considerable diversity of residue type and binding
interaction (Figure 3). One hypothesis suggests that resveratrol
binding is mainly attributed to the hydrophobic interactions
due to the presence of two benzene rings (Porat et al., 2006).
However, after further investigation, such notion is not entirely
true. While there are multiple pi-pi stacking and hydrophobic
interactions in some targets, like SULT1B1, QR2, TyrRS, cTnC,
they are very sparse in TTR and myosin-2, and almost none
in the res1 conformation of MAT2B. Similarly, binding could
also be attributed to the presence of substituted polar hydroxyl
groups present on both rings, as in the res1 conformation of
MAT2B (Shafqat et al., 2013). However, after careful observation,
this also doesn’t seem to be an essential feature as contradicted
by the examples of LTA4H, myosin-2 motor domain, PLA2,
and Sirt1 as discussed above. In this case, there are multiple
H-bonds to resveratrol hydroxyl groups via polar residues, but
there are almost negligible H-bonds in Sirt5, TTR and even none
in cTnC. Hence, in some cases the polar bonds formed between
the substituted hydroxyl groups on resveratrol and receptor polar
residues are extremely important in keeping the resveratrol in the
active site, and in others, the two rings seem to be essential for
making non-polar interactions. While still in others, there seems
to be a requirement of both the polar and non-polar units of
resveratrol to bind and act effectively. These binding interactions
with target residues are displayed in Figure 3.

Binding Residues

The simplest way to detect similarity between proteins is
comparing their primary sequence. Thus, we analyzed the
protein sequences of the resveratrol co-crystal structures
(Supplementary Table 2) by domain sequence similarity and also
by local binding site similarity. Sequence similarity is most useful
when comparing functional domains or motifs, for example Pfam
domains (Finn et al., 2016). The structural fold of a protein,
typically also a functional domain, in most cases is largely
conserved across a protein family, for example protein kinases,
or nuclear receptors. Overall protein folds are typically more
conserved than domain sequences. There exist protein families
that share the same fold, but vary considerably in sequence
similarity, for example within the GPCR transmembrane domain.
Local binding site similarity is another relevant measure of
relatedness that is independent of protein families defined by
domain sequence or structural similarity. Simplistically, binding
site similarities can be identified using just the amino acid
residues subsequence of the protein that interact with a small
molecule ligand or substrate. There are many methods to detect
such local binding site similarity including 2D and 3D methods.
Sequence identities for co-crystal structures ranged from about
0 to 29%, suggesting no significant similarity. Figure 2A shows
the phylogram of all protein sequences studied. It is also clear
from the diversity of the proteins binding resveratrol that they
do not share a common fold. Most relevant, however, we also
could not detect any similarity in the binding sites using the
Target Informatics (TIP) platform from Eidogen-Sertanty, Inc.
2
as illustrated in Figure 2B (Hambly et al., 2006). This lack
of any homology in the primary sequence, the overall fold and
the properties of the local resveratrol binding residues further
suggests that the targets of resveratrol are unusually diverse.
These results strongly suggest the lack of a common binding
pattern of resveratrol.

Secondary Structure of the Binding Site
Residues
Although polypharmacology drug targets can be dissimilar in
their primary domain sequence, proteins that bind to the same
compound typically show similarities in residue types, the overall
fold or secondary structure architecture of the binding sites
(Reddy and Zhang, 2013). However, when carefully examining
the secondary structure elements of resveratrol binding targets,
no obvious general binding motif can be identified (Figure 4).
Moreover, there is no detectable local binding site similarity
using the SiteSeeker algorithm (Ecker et al., 2009) (Figure 2B).
As discussed above, in most cases it is the alpha helix and
loop residues in and around the binding cavity that form the
binding brigade of the resveratrol ligand, for example PLA2,
SULT1B1, QR2, Sirt5, Sirt1. However, there are few cases, where
they specifically belong to a beta sheet and loop with none in an
alpha helix like those in LTA4H. Interestingly, there have been
some cases, where either the alpha helix (F1-ATPASE, cTnC) beta
sheet (TTR) or the loop (myosin-2 motor domain) are involved
exclusively. However, there are also instances where all three,
alpha helix, beta sheet and the loop motifs are involved together
(MAT2A, PPAR-γ, TyrRS). Thus, the dissimilarities in the overall
fold of the binding architecture of the resveratrol receptors point
to no conservation in their secondary structures.

Class of Targets
Typically, dual or polypharmacological inhibitors bind to the
same or a similar class of targets (Reddy and Zhang, 2013).
This is due to similar classes of proteins sharing some kind
of structural similarity for the incoming inhibitor to bind.
However, after investigating the classes of receptors modulated
by resveratrol based on their structure in the PDB, it became
clear that resveratrol binds to varied classes of proteins, labeling
this compound as highly promiscuous. The various classes
range from hydrolases (LTA4H, PLA2, F1-ATPASE, Sirt1)
oxidoreductases (QR2, MAT2A), transferases (SULT1B1), Ligases
(TyrRS), transcriptional regulators (PPAR-γ), Motor (Myosin2), contractile (cTnC), and transport proteins (TTR). Since the
2

http://www.eidogen.com/tip.php

Frontiers in Pharmacology | www.frontiersin.org

7

October 2018 | Volume 9 | Article 1201

Saqib et al.

Structural Interactions of Resveratrol

FIGURE 2 | (A) Phylogenetic analysis of resveratrol co-crystal structures. The analysis clearly shows that there is no similarity in the resveratrol targets. Image
produced by Phylogeny.fr server (http://www.phylogeny.fr/index.cgi) (Dereeper et al., 2008). (B) Resveratrol binding sites based on 15 resveratrol co-crystal structure
chains corresponding to Table 1. Binding sites were generated by the TIP platform, Eidogen Sertanty Inc. (Hambly et al., 2006). There is no significant observed
(above threshold) similarity among any of the resveratrol binding sites. Proteins shown: Leukotriene A4 hydrolase (3FTS), Phospholipase A2 (4QER), ATP synthase
subunit alpha (2JIZ), Sulfotransferase family cytosolic 1B member 1 (3CKL), NRH dehydrogenase (quinone) 2 (1SG0), Peroxisome proliferator-activated receptor
gamma (4JAZ), Transthyretin (5CR1), Troponin C (2I98), NAD-dependent protein deacetylase sirtuin-5 (4HDA), Tyrosine-tRNA ligase (4Q93), Myosin-2 heavy chain
(3MNQ), Methionine adenosyltransferase subunit beta (2YDX), Estrogen receptor (4PP6), NAD-dependent protein deacetylase sirtuin-1(5BTR).

Binding Pocket of the Targets

speculated that resveratrol only binds to the deep interior cavities
and pockets of the receptors. To some extent this was observed
to be true in many receptors discussed previously. For example,
LTA4H, F1-ATPASE, SULT1B1, QR2, PPAR-γ, Sirt5, and TyrRS.
However, further analysis reveals that it is surface buried in some

In order to determine if resveratrol displayed a preference
to a specific binding site cavity, we analyzed the 3-D space
filling models for each PDB structure (Figure 5). Resveratrol
is a substituted conjugated biphenyl structure, thus it could be
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FIGURE 3 | 2D representations of co-crystallized resveratrol-target interactions. Image created via Ligand Interactions Viewer in the Schrodinger Maestro Suite
2017. All protein PDB structures were prepared using the Protein Preparation Wizard where likely protonation states of residues and ligand at physiological pH were
generated. Green solid lines represent hydrophobic interactions, solid lines from the aromatic to other aromatic residues represent pi-stacking interactions, and solid
arrows display hydrogen bonding interactions (https://www.schrodinger.com/).

various diseases. The details on resveratrol’s mechanism of action
and pharmacology has been thoroughly discussed (Kovacic and
Somanathan, 2010). All of the modes of binding described above
for each target are summarized in Table 2.

cases like in the case of PLA2, TTR, myosin-2 motor domain res1
conformation in MAT2A While in others, like cTnC, it binds
to an open space on the receptor surface. These distinctions in
binding of resveratrol to either a deep cavity inside the receptor
or a shallow surface groove clearly defies the assumption of its
deep interior binding.

DISCUSSION

Mode of Action
Most of the known multi-target drugs generally inhibit or
activate more than one target at the same time, but do not
have the capability to activate one target and inhibit another
simultaneously. However, resveratrol displays various modes of
actions. We analyzed the mechanism of action of resveratrol on
each target by retrieving these annotations form the ChEMBL
21 database. As discussed above, in some instances it acts as
a direct inhibitor of the receptor, as seen in PPAR-γ, LTA4H,
PLA2, F1-ATPASE, SULT1B1, QR2, TTR. While acting as an
activator of a receptor function as in Sirt5, and Sirt1, and also
as a modulator, as seen in ERα, and TyrRS. Hence, resveratrol
has the ability to perform multiple functions of an inhibitor,
activator or a modulator depending on the targets involved in

Frontiers in Pharmacology | www.frontiersin.org

Resveratrol is only one of the numerous polyphenolic natural
products found in many red grape varieties (Siemann and
Creasy, 1992). In recent years, the interest in this molecule has
increased exponentially following studies that demonstrated
chemopreventive, cardioprotective, neuroprotective, antidiabetic, anti-aging, and anti-inflammatory properties (Wang
et al., 2002; Aziz et al., 2003; de la Lastra and Villegas, 2007; Albani
et al., 2010; Bereswill et al., 2010; Campagna and Rivas, 2010; Wu
et al., 2011). The myriad of beneficial activity has elicited a vast
interest toward the identification of target proteins of resveratrol.
Resveratrol, as a pharmacological agent, has a wide spectrum
of targets, where resveratrol inhibits, activates or modulates
its effects depending on the target (Hayashibara et al., 2002;
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FIGURE 4 | Secondary structure representations of binary complexes. Secondary structures of the resveratrol-binding residues are shown as green colored ribbons,
the remaining protein residues are shown in cornflower blue ribbons and the bound resveratrol is shown as orange colored sticks. The figure shows bound
resveratrol in (A) Transthyretin, TTR (PDB: 5CR1); (B) Troponin C, cTnC (PDB: 2L98); (C) Myosin-2 heavy chain myosin-2 motor domain (PDB: 3MNQ); and
(D) Tyrosine-tRNA ligase, TyrRS (PDB: 4Q93) binding sites. The non-conserved mode of secondary structure elements in the receptor binding site is evident. It
should be noted that the secondary structure representation is according to Chimera classification. (Image created by Chimera).

co-crystal structures, there is no significant similarity in the 3D
resveratrol binding sites across the different proteins. To the
best of our knowledge, this is the first review to describe the
binding interactions of resveratrol on a structural level to varied
scaffolds and elucidating that there is no common mode of
binding to its multitude of targets or even a significant subset
thereof.
After individually assessing the resveratrol-receptor
interactions, it could be easily deduced that resveratrol binds
varied classes of targets such as hydrolases, oxidoreductase,
metal-binding proteins, transcription regulators, motor proteins,
ligases contractile proteins, transferases, and transport proteins
etc. Moreover, the situation is further complicated by the
non-conserved mode of resveratrol binding within the pockets.
This is exemplified by its binding to a deep pocket in the
receptor active site as in LTA4H, F1-ATPASE, SULT1B1, QR2,
PPAR-γ, Sirt5, TyrRS, while it binds to a shallow groove on
PLA2, TTR, myosin-2 motor domain or even to a completely
exposed cavity on the receptor surface like cTnC. Interestingly,
resveratrol displays distinct binding modes even in the same
receptor like as seen in MAT2A, where one molecule binds
in a broad, shallow pocket while the other binds to a deep
narrow pocket inside the receptor. The varied profile of receptor
surface binding of resveratrol could be exemplified by Figure 5,
where, it could be clearly observed that resveratrol could bind
anywhere from a deep/buried to shallow/surface cavity, which
might be a consequential event where local arrangement, such as
conformational changes, play an integral role.

Low et al., 2010; Kai et al., 2010). Herein we present an overview
of the varied patterns and profiles of resveratrol target proteins
and the structural aspects of resveratrol binding with its multiple
targets as available in the PDB (Table 2). In order to do so, all
the co-crystal structures of various targets inhibited, activated
or modulated by resveratrol were extensively evaluated. We
then reviewed the resveratrol polypharmacology at various
levels. These include homology in primary structure and class of
binding targets, mode of resveratrol binding, fold or secondary
structure of the binding site, conservation in binding site
residues, and mode of action (Table 2). After a detailed analysis,
it appears that resveratrol displays interfamily promiscuity,
which is the highest degree of promiscuity and is rarely observed
in clinical compounds (Hu and Bajorath, 2013).

Structural Modes of Binding
Sequence identity generally helps to identify common structural
pattern or motifs, which may aid in understanding the binding
mode of a multi-target drug or inhibitor. The protein binding
site similarity is key to drug promiscuity, which also confers
similar binding interactions with a common ligand. For example,
Haupt et al. (2013) have demonstrated that 71% of the drugs they
used in their study have at least two targets with similar binding
sites. Hence similarity in the binding site is an important feature
for a promiscuous drug to bind to multiple targets. However,
when primary structures of the resveratrol targets were evaluated,
it was observed that they do not share significant sequence
identity. More importantly, based on the available resveratrol
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FIGURE 5 | Surface representation of binary complexes. The receptors are shown as surface representation (red color) and the bound resveratrol is shown as CPK
(green color). The figure above shows bound resveratrol in prototype complexes for each function: (A) Leukotriene A4 hydrolase, LTA4H (PDB: 3FTS), inhibitory;
(B) Estrogen receptor, ERα (PDB:4PP6) modulatory; (C) NAD-dependent protein deacetylase sirtuin-1, Sirt1 (PDB: 5BTR), activatory; (D) Transthyretin, TTR (PDB:
5CR1), Inhibitory. The above figures highlights resveratrol’s dissimilar binding modes among different and also similar targets; including deep and shallow (surface)
binding pockets.

The secondary structure pattern of resveratrol binding
site residues is quite varied among its targets. While some
prominently form a surrounding alpha helix and loop as in
PLA2, SULT1B1, QR2, Sirt5, and Sirt1. In others, it specifically
belongs to a beta sheet and a loop with no alpha helix, such as
with LTA4H. Still others display all three secondary structures
including an alpha helix, beta sheet and a loop jointly forming
the binding residues, such as MAT2, PPAR-γ, and TyrRS. The
varied profile of secondary structure elements of resveratrol
targets is displayed in Figure 4. This diversity in binding may
be attributed to the local conformation changes that the proteins
undergo due to resveratrol binding. This is best exemplified in
the case of Sirt1 activation by resveratrol discussed above, where
the latter provokes a structural conformational change in the
former, thereby allowing the binding of the acetylated substrate
and NAD+ and ultimately enhancing the enzymatic activity.
These studies point toward a dynamic mode of binding between
the incoming resveratrol and the target, where conformational
changes are induced as a result.

Resveratrol is composed of a conjugated phenolic ring system
that attains either a planer, snugly fit, or a flat conformation
inside the receptor binding site. It should be noted that the most
common binding features among pre-clinical and clinical small
molecules are arene ring systems substituted with hydrogen bond
donors and acceptors. These phenolic rings could attribute to a
series of hydrophobic interactions that serve as important forces
of target binding. On this basis, this moiety could be considered
a highly important and indispensable part of receptor binding
by making critical non-polar hydrophobic interactions. However,
closer examination of the binding site residues revealed that in
some cases only hydrophobic interactions are involved between
resveratrol and its targets as in TyrRS, and cTnC, but they
are predominantly polar in LTA4H, myosin-2 motor domain,
PLA2, Sirt1 and res1 conformation of MAT2A. Furthermore,
considering that there have been instances where hydrogen
bonding through the hydroxyl substituents solely constitute
target binding, one might speculate the indispensability of
polar hydroxyl groups for resveratrol binding to varied targets.
However, as discussed above, this is not entirely true in the cases
of TyrRS, and cTnC, where the binding is strictly non-polar
in nature. On the other hand, there are instances where there
is a mix of both polar and non-polar interactions as in TyrRS
and QR2. The detailed atomic interactions of resveratrol with
its binding partners have been elucidated in Figure 3, where 2D resveratrol binding interactions with each of the targets are
displayed. It is easily deduced from the figure that resveratrol does
not show any specific pattern in binding site residue interactions,
which could be either purely hydrophobic, polar or both.

Frontiers in Pharmacology | www.frontiersin.org

Mode of Action
Inhibitory functions played by resveratrol are attributed to its
competitive binding to the receptor for its natural substrate
(LTA4H, PLA2, QR2 etc.). Resveratrol also incites activity by
binding in conjugation with another activator whereby they
synergistically perform receptor activation. This is exemplified
by Sirt1 where two resveratrol molecules promote tighter
binding between Sirt1 and the p53-AMC peptide leading to the
stimulation of Sirt1 activity. Resveratrol displays its modulatory
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Ile19
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Binding pocket

TABLE 2 | Structural aspects of Resveratrol binding to various targets.
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linked via an N-monosubstituted carbamate ester bond to
derivatives of glycerol or galactose (Biasutto et al., 2014). Thus,
conferring higher water solubility, improving bioavailability, and
offering initial protection from quick metabolic degradation, and
elimination.
There has even been significant interest by natural product
chemists to isolate, characterize and synthesize a more potent
resveratrol-like natural product that is a part of the same,
or a stress-response, biosynthetic pathway. These compounds
are known as secondary metabolites and are not essential
for the survival of the organism, but are produced in small
amounts due to an external trigger. While this approach may
not necessarily account for positive changes to ADMET, they
may display superior, and more targeted biological activity. The
overarching obstacle for this approach is obtaining these complex
molecules in appreciable amounts, as extraction would be nearly
impossible due to the negligible amounts produced by the
organism throughout its lifetime. Several research groups have
successfully synthesized oligomeric resveratrol natural products
in quantities needed for biological testing. Snyder et al. (2011)
accessed Caraphenol A in gram scale quantities, along with
efficiently synthesizing several other compounds with promising
in vitro activity, such as Pallidol, Ampelopsin F, Vaticanol A, and
Hopeahainol A. More recently, Keylor et al. (2016) developed a
controlled radical methodology to efficiently access resveratrol
tetramers such as Nepalensinol B, and Vateriaphenol C. However,
it is yet to be demonstrated if these natural products will offer any
improved activity in vivo, and in primate models.
While there have been no real marked advances in translating
the intriguing bioactivity of resveratrol into an efficacious drug
via a typical medicinal chemistry approach. Global systems-wide
analysis such as genome-wide transcriptional responses of the
effects of resveratrol offer an alternative approach. Recently,
researchers have displayed interest in investigating resveratrol’s
activity at a systems level. Fang et al. (2017) predicted possible
other targets of interest for the anti-cancer effects of resveratrol
based on statistical analysis of publicly available databases of
deposited bioactivity (such as ChEMBL, Binding DB, and TCGA)
combined with by machine learning. Crossland et al. (2017)
observed that while resveratrol did reverse transcription of genes
that are the most perturbed due to aging in patient derived
muscle cells and tissue, it did not reverse the disease (aging)
gene signature when they observed the effect at a systems level.
Interestingly, the authors state that based on their findings, SIRT1
and AMPK may not be a regulator of healthy aging, further
explaining the lack of translational activity for resveratrol.
The Library of Integrated Cellular Signatures (LINCS) is an
NIH common fund project established in 2013 that has the
underlying goal to understand the effect of perturbagens at
cellular level for disease and health states (Keenan et al., 2018).
Resveratrol is one of many perturbagens tested in the L1000 highthroughput reduced representation genome-wide transcriptional
profiling assay developed by The Broad Institute enabling rapid
transcriptional profiling of large compound libraries across many
cell lines (Subramanian et al., 2017). Analysis of this data
is being carried out in hopes of better understanding on a
holistic level how resveratrol, and other perturbagens, modulate

action in TyrRS by binding and hence nullifying the receptor’s
catalytic activity and further directing it to a nuclear function.
Another contrasting character of resveratrol’s non-conserved
mode of binding is further demonstrated by sirtuin binding.
The observed mode of action is inhibitory for one class of
sirtuin (Sirt2), while it plays an activator role for Sirt1 and
Sirt5. Even in its activator role, there are distinct binding modes
of resveratrol. Three resveratrol molecules bind to Sirt1, but
only two molecules mediate the interaction between the Sirt1
N-terminal domain and the 7-amino-4-methylcoumarin (AMC)containing peptide (p53-AMC) to stimulate Sirt1 activity. While
the third resveratrol molecule further strengthens this binding
by interacting with both the Sirt1 catalytic domain and the
peptide. Similarly, in ERα, resveratrol binds as two different
conformers, where the first conformer shows the canonical pphenol of resveratrol mimicking the natural substrate, whereas in
the second conformer, it is flipped. Thus, resveratrol could bind
to the same protein in two or even three distinct binding modes
such as in MAT2.

Drug Development Opportunities
While there has been a multitude of impressive biological
activity produced in vitro, and in vivo studies, there has
yet to be an FDA approved use of resveratrol in humans.
Resveratrol exerts its beneficial effects at low micromolar
concentrations, owing to observed low binding constants
across targets (Supplementary Table 1), coupled with overall
poor ADMET (Absorption, Distribution, Metabolism, Excretion,
Toxicity) properties. Because of its truly non-conserved mode
of binding described at length in this review, it lacks specificity
for any particular target, or interactions. Moreover, resveratrol
demonstrates poor bioavailability and is rapidly excreted through
metabolic hydrogenation of the aliphatic double bond, as well as
glucuronidation and sulfation of the hydroxyl moieties (Wang
and Sang, 2018).
However, considering the demonstrated therapeutic potential
of resveratrol, there has been significant interest in synthesizing
more potent derivatives with increased binding and improved
ADMET. For example, aza-modified compounds developed
by Fujita et al resulted in an increase in potency (Fujita
et al., 2012), and a series of bridged stilbene derivatives
demonstrated submicromolar inhibition of both COX-1 and
COX-2 (Handler et al., 2007). In yet another study, resveratrol
stilbene derivatives with modifications at the 4’ position of
the β-ring were synthesized with higher potency for Sirt1
activation and lifespan extension in Saccharomyces cerevisiae
(Howitz et al., 2003). Bioavailability was increased with
analogue 3,4,5,40 -tetrahydroxystilbene, although elimination is
also likely to increase (Lu et al., 2001). Sirtris, acquired
by GlaxoSmithKlein in 2008, was a company dedicated to
creating sirtuin activators, and patented a proprietary resveratrol
formulation to improve bioavailability by utilizing microsphere
particles, but no improvement in activity was obtained from
either efforts (Schmidt, 2010). Yet, another strategy to improve
the pharmacological benefits of resveratrol is through a prodrug
approach. One promising design was the usage of amino acid
carbamates to partially, or fully modify the hydroxyl groups
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After careful analysis of the various aspects of target
binding, one cannot form a consensus of resveratrol’s binding
characteristics, and it should be regarded as a highly promiscuous
compound. Although, one feature that is clear from its mode
of action is its positive impact on diseases. Through inhibition,
activation or modulation resveratrol displays varied therapeutic
potential. A different approach of analyzing resveratrol’s impact
on disease from a systems biology level may yield new insights
for utilizing resveratrol-like compounds as polypharmacological
medicine.
All LINCS data and curated bioactivity data of resveratrol are
available from the LINCS Data Portal at http://lincsportal.ccs.
miami.edu/SmallMolecules/view/LSM-42917.

disease. For example, the transcriptional impact across many
cell lines perturbations with similar profiles (e.g., connectivity)
can be explored via the Clue platform at the Broad Institute3 .
All LINCS datasets are available via the LINCS Data Portal
(Koleti et al., 2018). Analysis of this data is also of interest to
another NIH common fund project, Illuminating the Druggable
Genome (IDG), which seeks to discover drug targets that are
currently underexplored or even unknown. Through the analysis
of “big” genome-wide profiling datasets and potential novel
targets, it may be possible to better understand the mechanisms,
including novel pathways and possibly novel protein targets that
underlie resveratrol’s beneficial health effects. All of these would
improve our understanding of Nature’s micromolar love-affair
with resveratrol and guide the way to the development of novel
therapeutics that overcome promiscuity and finally harness its
polypharmacological potential and associated beneficial health
effects.
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CONCLUSION
Resveratrol, (trans-3,40 ,5-trihydroxystilbene) is a polyphenolic
phytoalexin present in many plants. It has gained much
attention since the 1980’s, but translation of resveratrol’s
intriguing bioactivity from the bench to the clinic has yet to
be demonstrated. There are multiple reasons for the failure
to translate activity in primates, including the interfamily
promiscuity, coupled with poor drug-like physicochemical and
ADMET properties. However, because of the broad therapeutic
profile of this phytochemical, there are multiple ongoing efforts
to exploit its pharmacology and fully tap its pharmaceutical
potential, despite a generally low observed activity against its
targets.
In the current review, we have covered almost all of the cocrystal structures of resveratrol involved in inhibition, activation
and modulation of the target proteins associated with various
diseases. The analyses of resveratrol with its targets revealed
that they share no significant similarity in domain sequence,
structural fold or even the local 3D binding site. Thorough
analysis of various resveratrol-receptor complexes reveals that
the compound does not have any preferred mode of binding.
This provides a clue to its heterogeneous nature of binding
where it has no special preference to a hydrophobic groove or
a charged surface. Investigation of the co-crystal structures of
resveratrol-protein complexes at the atomic level also revealed
its non-conserved mode of binding. Analyses of binding patterns
reveal that the compound has no preference to acidic, basic
or neutral amino acids and could potentially bind to any or
all of the categories. Similarly, the secondary structures of
resveratrol’s binding partners have little in common, with binding
site architecture ranging from primarily alpha helix, beta sheet,
or merely loops or in some cases a combination of all three.
Even the mode of action of resveratrol is diverse in different
targets, where it displays inhibitory, activatory and modulatory
activity.
3
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